JP2017535551A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535551A5
JP2017535551A5 JP2017526138A JP2017526138A JP2017535551A5 JP 2017535551 A5 JP2017535551 A5 JP 2017535551A5 JP 2017526138 A JP2017526138 A JP 2017526138A JP 2017526138 A JP2017526138 A JP 2017526138A JP 2017535551 A5 JP2017535551 A5 JP 2017535551A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
vegf
compound
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535551A (ja
JP6863892B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050720 external-priority patent/WO2016077878A1/en
Publication of JP2017535551A publication Critical patent/JP2017535551A/ja
Publication of JP2017535551A5 publication Critical patent/JP2017535551A5/ja
Application granted granted Critical
Publication of JP6863892B2 publication Critical patent/JP6863892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526138A 2014-11-17 2015-11-17 脳卒中を治療又は予防する方法 Active JP6863892B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904606 2014-11-17
AU2014904606A AU2014904606A0 (en) 2014-11-17 Method of treating or preventing stroke
PCT/AU2015/050720 WO2016077878A1 (en) 2014-11-17 2015-11-17 Method of treating or preventing stroke

Publications (3)

Publication Number Publication Date
JP2017535551A JP2017535551A (ja) 2017-11-30
JP2017535551A5 true JP2017535551A5 (enExample) 2018-12-06
JP6863892B2 JP6863892B2 (ja) 2021-04-21

Family

ID=56012959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526138A Active JP6863892B2 (ja) 2014-11-17 2015-11-17 脳卒中を治療又は予防する方法

Country Status (12)

Country Link
US (2) US10336821B2 (enExample)
EP (1) EP3220952B1 (enExample)
JP (1) JP6863892B2 (enExample)
KR (1) KR102560025B1 (enExample)
CN (1) CN107106681B (enExample)
AU (1) AU2015349610B2 (enExample)
CA (1) CA2967070C (enExample)
DK (1) DK3220952T3 (enExample)
ES (1) ES2881303T3 (enExample)
PL (1) PL3220952T3 (enExample)
RU (1) RU2744909C2 (enExample)
WO (1) WO2016077878A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031943B1 (pt) 2011-06-13 2021-10-13 Csl Limited Composição que compreende proteínas e anticorpos contra g-csfr
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
EP3681497A4 (en) * 2017-09-13 2021-06-02 The Regents of The University of Michigan INHIBITION OF KINASE C PROTEIN TO EXTEND PLASMINOGEN TISSUE ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
DK1781321T3 (da) * 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
EP2500352A1 (en) * 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
WO2009036149A2 (en) * 2007-09-15 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods for treatment of degenerative disease associated with apoptosis
EP2271365A4 (en) * 2008-04-09 2011-10-26 Ludwig Inst Cancer Res REGULATION OF FATTY ACID TRANSPORTERS
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
EP3530286A1 (en) 2013-11-28 2019-08-28 CSL Limited Method of treating diabetic nephropathy
CA2932465C (en) 2013-12-18 2023-08-22 Csl Limited Methods of treating wounds in a diabetic subject

Similar Documents

Publication Publication Date Title
JP2017535551A5 (enExample)
JP2019523295A5 (enExample)
RU2017120031A (ru) Способ лечения или предотвращения инсульта
JP2022534020A (ja) Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2017506626A5 (enExample)
US11319368B2 (en) Treatment of hepatotoxicity with IL-11 antibody
JP2019505527A5 (enExample)
JP2017113019A5 (enExample)
RU2018135371A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
JP2019528306A5 (enExample)
EP4309734A1 (en) Methods for treating cardiovascular disease
CN102307899A (zh) 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
TWI834254B (zh) α-烯醇酶拮抗劑治療纖維化疾病之用途
JP2021501138A (ja) 虚血性再灌流障害を治療するための酸化特異的エピトープの阻害
JP7675440B2 (ja) 炎症性肺疾患の予防及び／又は治療剤
TWI566780B (zh) 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途
US20230049147A1 (en) Anti-il-36r antibodies for the treatment of a fibrotic condition
WO2016093700A2 (en) Immunoglobulin-like molecules directed against fibronectin-eda
US20250282861A1 (en) Mfap4 and treatment of fibrosis
JP7565607B2 (ja) 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト
Wang et al. Emerging Role of CXCR4 in Fibrosis
AR130862A1 (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
WO1999058150A1 (en) Preventives/remedies for hepatic cirrhosis
EA047713B1 (ru) Лечение гепатотоксичности
Chan CCR1-deficiency improved survival and attenuated cardiac remodeling post-myocardial infarction